Willan, Andrew R.; Eckermann, Simon - In: PharmacoEconomics 30 (2012) 6, pp. 447-459
Previous application of value-of-information methods to optimal clinical trial design have predominantly taken a societal decision-making perspective, implicitly assuming that healthcare costs are covered through public expenditure and trial research is funded by government or donation-based...